The Venture Capital Fund managed by RusBioVentures LLC was formed as an investment partnership agreement within the framework of Federal Law No. 335-FZ On Investment Partnership, dated November 28, 2011 (as subsequently amended by Federal Law No. 220-FZ, dated July 21, 2014). The first closing of the Fund in the amount of about RUB mln 2.07 was held on October 10, 2014. Thus, the fund became the first major independent investment partnership, established in the Russian Federation.
R-Pharm CJSC, a Russian private pharmaceutical company is the Anchor investor. It provides scientific and managerial expertise as well as cash assets. The fund's managing partner is RusBioVentures LLC, a company created by venture market professionals who have experience of successful domestic and international transactions in the field of biomedicine.
The fund starts investing into projects in Biotechnology, Pharmacy, Medicine and their related areas. The fund's investment strategy was formed, taking into account the features and needs of the Russian and world markets, characterized by an increasing convergence of technologies (biological, engineering, chemical, computer, and others), as well as the strengths of the management team. It is expected that the portfolio will include the balance of:
High-risk, unique projects at a relatively early stage, which have the potential of multiple capitalization growth,
Moderate-risk projects at the later stages or with a shorter life cycle (e.g., bio-IT), and
Low-risk projects that are already on, or close to the market, including syndicated and (or) territorial transactions with the world's leading venture capital firms.